Curcumin is a turmeric, antioxidative compound, well-known of its anti-cancer properties. Nowadays more and more effort is made in the field of enhancing the efficiency of the anticancer the...
In a retrospective review, we identified 332 patients with 338 pathologically diagnosed primary oropharyngeal carcinomas (OPC) between January 2013 and March 2020 with known p16/HPV status f...
Overexpression of polycomb protein contributes to epigenetic repression in oral squamous cell carcinoma (OSCC) ensuing in poor prognosis and aggressive phenotype. Several plant-based compoun...
Store-operated calcium entry (SOCE) through STIM-gated ORAI channels governs vital cellular functions. In this context, SOCE controls cellular redox signaling and is itself regulated by redo...
To analyze conditional survival estimates of patients with esophageal cancer who underwent curative resection.Conditional survival reflects dynamic prognosis updated to the current status an...
The ongoing UNIFI long-term extension evaluates subcutaneous ustekinumab for moderate-to-severe ulcerative colitis (UC) from weeks 44 through 220.To assess efficacy (through week 92) and saf...
Overall survival also extended with conjugate treatment In a small, phase II trial, patients with advanced gastric cancer were far more likely to respond to conjugate therapy with trastuzum...
HERO findings also confirm fewer cardiovascular events with relugolix More than 96% of men with advanced prostate cancer who were treated with relugolix, an oral, highly selective gonadatro...
FRIDAY, May 29, 2020 (HealthDay News) -- For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compare...
To determine the maximum tolerated dose (MTD) of stereotactic ablative radiotherapy (SABR) in combination with immunotherapy for the treatment of metastatic melanoma. The study also investig...
The chemical constituents of the roots and bark of Azadirachta indica were investigated, leading to the isolation of six tricyclic diterpenoids and four limonoids including a new compound, a...
The widely used in vitro invasion assays for head and neck squamous cell carcinoma (HNSCC) are wound healing, transwell, and organotypic assays. However, these are still lab-intensive and ti...
Melanoma is a very lethal tumor type that easily spreads and colonizes regional and distant tissues. Crucial phenotypic changes that favor melanoma metastasis are interposed by the tumor mic...
Few prospective studies on outcomes in CSCC have been performed, and outcomes for patients treated specifically by Mohs micrographic surgery (MS) have not been described in the US. To addres...
Although previous studies suggest objective responses with BRAF and MEK inhibitors in the majority of patients with BRAF-mutant melanoma, data also suggest that acquired resistance limits re...
Over 90 000 people are expected to be diagnosed with melanoma in the United States this year. The development of brain metastases is particularly difficult to manage. Over the past few years...
Since not too many human uterus cervical squamous cell carcinoma (CSCC) cell lines in existance, efficient isolation, culture and purification protocols for primary CSCC cells were optimized...
The rise of programmed death-1 (PD-1)/PD-L1 immune checkpoint inhibitor therapy has been one of the most promising developments in melanoma research. However, not all the melanoma patients r...
Cutaneous squamous cell carcinoma (cSCC) is the most prominent tumor of non-melanoma skin cancers and the most aggressive tumor among keratinocyte carcinoma of the skin, showing a high poten...
CDKN2A, CDK4, and POT1 are well-established melanoma-susceptibility genes.We evaluated melanoma histopathology for individuals with germline mutations of CDKN2A, CDK4, and POT1.We assessed h...
The latest articles and insights from your colleagues in your specialty(ies) of choice.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
